Clinical Trial

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RG6496 in Huntington's Disease

Study acronym: POINT-HD
Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a first-in-human (FIH) study of RG6496 that will assess the safety and tolerability of single-ascending doses of RG6496 administered to huntington's disease gene expansion carriers (HDGECs). The study consists of two parts: Part 1 \[single-ascending dose\] followed by Part 2 \[open-label extension (OLE)\].
Protocol Amendment History 3 changes
critical Enrollment closed, study ongoing 2026-08-04
notable Primary completion pushed: 2027-12-11 -> 2028-02-28 2026-06-03
minor Completion pushed: 2029-03-05 -> 2029-05-23 2026-06-03
Trial Details
NCT Number NCT07246941
Lead Sponsor Hoffmann-La Roche
Conditions Huntington's Disease
Enrollment 40 participants
Start Date 2025-11-19
Primary Completion 2028-02-28 (estimated)
Study Completion 2029-05-23 (estimated)
Updated on ClinicalTrials.gov 2026-08-03